Filing Details
- Accession Number:
- 0001209191-20-064857
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-22 16:55:26
- Reporting Period:
- 2020-12-21
- Accepted Time:
- 2020-12-22 16:55:26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1674416 | Crispr Therapeutics Ag | CRSP | Biological Products, (No Disgnostic Substances) (2836) | 473173478 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1713637 | W Tony Ho | C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139 | Executive Vp, Head Of R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2020-12-21 | 23,551 | $16.90 | 57,515 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2020-12-21 | 1,700 | $148.11 | 55,815 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-12-21 | 900 | $149.18 | 54,915 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-12-21 | 1,600 | $150.16 | 53,315 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-12-21 | 1,100 | $151.58 | 52,215 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-12-21 | 500 | $152.41 | 51,715 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-12-21 | 1,400 | $147.05 | 50,315 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-12-21 | 8,400 | $148.38 | 41,915 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-12-21 | 5,000 | $149.73 | 36,915 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-12-21 | 2,951 | $150.61 | 33,964 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Stock Option (right to buy) | Disposition | 2020-12-21 | 23,551 | $0.00 | 23,551 | $16.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 236,449 | 2027-08-01 | No | 4 | M | Direct |
Footnotes
- Includes 217 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.44 to $148.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.69 to $149.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.755 to $150.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.04 to $152.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.00 to $147.125, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.19 to $149.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.20 to $150.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.44 to $151.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- This option was granted on August 1, 2017 with respect to 260,000 Common Shares of which 25% vested on 8/1/2018 and the remaining 75% vest in 36 equal monthly installments on the final day of each succeeding calendar month.
Billionaire Hedge Funds
